OneAlphaMed combined targeted social media algorithms with an activated DOL network to accelerate clinical trial enrollment by 40% — filling sites in 8 markets without a single traditional recruitment poster.
Industry / Specialty
Pharmaceutical & Healthcare
Scale / Audience
15,000+ HCPs
Core Solutions
Co-created Certification
Time to Value
Pan-India Deployment
Stop funding clicks. Start building undisputed credibility for your brand today.
A global clinical research organization managing a Phase III oncology trial across 24 sites in 8 markets faced a critical enrollment shortfall at the 6-month mark — with only 38% of target patients enrolled against a 65% milestone requirement. Traditional recruitment methods — site posters, GP referral letters, and patient advocacy organization outreach — were generating insufficient volume at the required speed. OneAlphaMed deployed a precision digital recruitment campaign combining targeted social media patient outreach with coordinated oncology DOL network activation for HCP referral acceleration — increasing monthly enrollment rates by 40% and hitting the trial’s enrollment target 11 weeks ahead of the revised deadline.
Clinical trial enrollment failure is the single most common cause of Phase III drug development delays — and it is almost always predictable and preventable with the right digital strategy.
Site coordinators had already exhausted the standard recruitment toolkit: GP referral letters had been distributed, patient advocacy organization newsletters had been circulated, and site waiting room posters had been displayed for 4 months. Despite these efforts, the monthly enrollment rate had plateaued well below target, with coordinators reporting that they had effectively reached the readily identifiable eligible patient pool within their existing referral networks.
The eligible patient population for the trial was dispersed across both oncology specialist practices and community health settings — but the trial's HCP outreach had focused almost exclusively on academic and tertiary oncology centers. A large proportion of eligible patients were being managed by community oncologists and general internists who were entirely outside the trial's existing referral network and had no awareness of the enrollment opportunity.
Despite growing evidence that patients actively search online for clinical trial opportunities, the trial had no digital patient-facing presence beyond a basic entry on the clinical trials registry — providing no mechanism for motivated, potentially eligible patients to find the trial, assess their potential eligibility, or initiate contact with a trial site.
OneAlphaMed deployed a dual-track digital strategy simultaneously addressing both patient discovery and HCP referral network expansion.
OneAlphaMed developed and deployed targeted paid social campaigns on Facebook, Instagram, and patient health platform networks — using carefully constructed audience targeting parameters (age range, condition-related interest signals, geographic proximity to trial sites) to reach potentially eligible patients with plain-language trial awareness content. All targeting parameters and content were reviewed and approved by the trial's IRB/Ethics Committee before deployment.
OneAlphaMed identified and activated 45 community oncology Digital Opinion Leaders — practicing oncologists with active social media presence and established peer followings — who were briefed on the trial's enrollment criteria and provided with pre-approved, shareable scientific content that they could post organically to their networks. This extended the referral awareness campaign to thousands of community oncologists outside the trial's existing academic referral network.
OneAlphaMed built a GDPR-compliant digital pre-screening tool — accessible via a dedicated trial information microsite — that allowed potentially eligible patients to complete a structured eligibility questionnaire and, if pre-screened positive, receive automatic referral to their nearest trial site with contact details and a direct scheduler link. This reduced the site coordination burden and improved the quality of referred patients presenting for formal screening.
Closing the Patient Discovery Gap.
The strategic insight was recognizing that eligible patients and willing HCPs both exist in sufficient numbers — the limiting factor is the discovery infrastructure connecting them to the trial. By building a precision digital bridge between potentially eligible patients searching online and community HCPs who had never heard of the enrollment opportunity, OneAlphaMed converted a enrollment crisis into a systems problem with a digital solution.
The digital enrollment campaign transformed a plateaued recruitment timeline into an accelerating momentum story.
The digital recruitment program not only resolved the immediate enrollment crisis but established a replicable infrastructure for all of the organization's future Phase III trials.
Received a measurably improved quality of pre-referred patients — having completed digital pre-screening before their first site contact — resulting in a 28% improvement in formal screen-to-enroll conversion rates and a significant reduction in the coordinator time spent screening ineligible patients. Sites reported that the digital pre-screening funnel was the single most impactful operational improvement in the trial's recruitment program.
Gained awareness of and access to a potentially life-changing clinical trial opportunity through channels they were already using — social media and health information websites — removing the traditional barrier of requiring a clinician referral as the sole pathway to trial discovery. Several enrolled patients explicitly stated in post-enrollment surveys that they had been actively searching for trial opportunities for months before the digital campaign made the connection possible.
Avoided the multi-million dollar cost of extending trial timelines and activating additional sites — the standard operational response to an enrollment crisis — by addressing the root cause (patient and HCP discovery gaps) rather than the symptom (low enrollment numbers). The digital recruitment methodology has since been incorporated into the sponsor's standard Phase III trial operational planning template.
All patient-facing digital content and targeting parameters require specific IRB/Ethics Committee review and approval before deployment — we include detailed documentation of the targeting methodology, the content of all ads and landing pages, and the data handling protocols in the ethics submission package. In most jurisdictions, digital patient recruitment is now a well-established category with documented review procedures, and we provide site teams with a complete regulatory submission package to streamline the approval process.
We track a specific digital recruitment quality scorecard including pre-screen-to-formal-screen conversion rate, formal-screen-to-enroll conversion rate, screening failure reason distribution, and post-enrollment retention rate at the 3-month mark. Our experience across multiple trials shows that digitally pre-screened patients have a marginally lower formal-screen-to-enroll rate (due to their self-selected rather than clinician-referred status) but a significantly higher post-enrollment retention rate, likely due to higher intrinsic trial motivation.
The pre-screening tool collects only the minimum data required for eligibility assessment — no personal health information beyond the eligibility criteria questions — and operates under a fully informed consent framework with clear explanation of data usage. Collected data is stored exclusively on secure servers under the applicable health data protection framework, is accessible only to the trial's IRB-approved research team, and is deleted within 30 days for patients who do not proceed to formal site referral.
+91 9811660635
info@onealphamed.com
2414, Ground Floor, Aravali Vihar, Sector 49 Faridabad, Haryana – 121001 India
Copyright © 2026 OneAlphaMed. All Rights Reserved.